France's Transgene is taking the wraps off of positive Phase IIb data for its experimental cancer vaccine, TG4010. The European trial of 148 patients saw progression-free survival of 44 percent of patients for six months compared to 35 percent in the control arm. The cancer vaccine uses the Modified Vaccinia Anakara virus vector to spur an immune response.
"These results clearly warrant pursuing development into a Phase III program and we will be seeking to establish a partnership in order to complete the last stages of clinical development and bring TG4010 to the market," said CEO Philippe Archinard.
- check out the press release [1]
- read the AFX report [2]
Related Article:
Big Pharma takes an interest in cancer vaccines [3]
Links:
[1] http://www.fiercebiotech.com/press-releases/transgene-transgenes-therapeutic-vaccine-tg4010-meets-primary-endpoint-non-small-cell
[2] http://www.forbes.com/afxnewslimited/feeds/afx/2008/06/02/afx5068192.html
[3] http://www.fiercebiotech.com/story/big-pharma-takes-interest-cancer-vaccines/2007-09-19